Company profile: Veralox Therapeutics
1.1 - Company Overview
Company description
- Provider of small molecule therapeutics targeting the 12-LOX pathway for thrombosis and Type 1 Diabetes. Products include VLX-1005, a first-in-class drug for treating Heparin-Induced Thrombocytopenia by inhibiting platelet activation through 12-LOX pathway inhibition; VLX-2000 Series under development to protect β cells and improve insulin production; plus an Expanded Access Program for investigational medicines.
Products and services
- Expanded Access Program: Investigational, offers medicines to patients unable to participate in clinical trials under specific conditions
- VLX-1005: First-in-class, treats Heparin-Induced Thrombocytopenia by inhibiting platelet activation through 12-LOX pathway inhibition, directly targeting platelet-driven mechanisms in HIT
- VLX-2000 Series: Under development, focuses on 12-LOX inhibition to protect β cells and improve insulin production for Type 1 Diabetes and other undisclosed indications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Veralox Therapeutics
Omniox
HQ: United States
Website
- Description: Provider of technologies used to identify and treat cancer, cardiovascular disease, and trauma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Omniox company profile →
CellaVision
HQ: Sweden
Website
- Description: Provider of digital hematology microscopy solutions, including analyzers, instruments, reagents, and software, that automate and simplify routine analysis of blood and other body fluids and support hematology laboratory differentials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CellaVision company profile →
Biomaneo
HQ: France
Website
- Description: Provider of medical analysis kits for the detailed analysis of proteins by mass spectrometry.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biomaneo company profile →
Fenwal
HQ: United States
Website
- Description: Provider of blood technology solutions supporting transfusion medicine and cell therapies; develops products that improve the safety and availability of blood, helping shape transfusion practice and make life-saving blood therapies available to medical professionals and patients worldwide.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fenwal company profile →
Quotient
HQ: United States
Website
- Description: Provider of transfusion and blood bank diagnostics solutions, including MosaiQ, a fully automated in‑vitro platform performing multiple tests on a single patient sample to optimize laboratory resources and shorten time to diagnosis; Alba, manual reagents for blood bank diagnostics with technical and customer support; and MosaiQ AiPlex CTD, a microarray immunoassay for connective tissue diseases that detects multiple autoantibodies in one panel.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quotient company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Veralox Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Veralox Therapeutics
2.2 - Growth funds investing in similar companies to Veralox Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Veralox Therapeutics
4.2 - Public trading comparable groups for Veralox Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →